Sep 8, 2026 · 6 min
Drug setback and cyberattack rattle major stock movers
Novartis Drop; Boston Scientific Cyberattack; Intel Rises
The episode connects company-specific shocks at Novartis and Boston Scientific with Intel’s pricing plans, then widens the lens to cities adapting to rapid growth.
- 1Novartis shares fell after a muscle-wasting disease treatment missed its primary late-stage trial endpoint.
- 2Boston Scientific expects cyberattack-related pressure on sales growth and adjusted earnings, though some lost revenue may return.
- 3Intel rose on reports of planned CPU price increases as the episode previews AI-enabled planning for smarter cities.
Don't miss
Boston Scientific’s cyberattack is presented as a market-moving operational problem, with weaker sales and earnings guidance but possible recovery of lost revenue.
The brief
The episode opens with a question larger than the market: how can cities absorb rapid urbanization while building smarter, more innovative infrastructure?
The stock roundup then turns to Novartis, whose shares plunged after a muscle-wasting disease treatment failed to meet its primary late-stage trial endpoint, deepening pipeline concerns.
Boston Scientific faces a different shock: a previously reported cyberattack is weighing on operations, sales growth, and adjusted earnings guidance for the third quarter and full year.
Intel moved higher after reports, attributed to unnamed sources cited by Digitimes, that it plans to raise CPU prices by about 10 percent.
The closing Economy of Scale preview links artificial intelligence and long-term planning to smarter urban systems, including Dubai’s response to rapid population growth.
What was said on this episode
9 statements · 3 positive · 6 negative
Novartis’s muscle-wasting disease treatment failed its primary trial endpoint.
“The treatment they have for muscle-wasting diseases failing to meet the primary endpoint in a trial.”
Listen at 0:47
The trial failure is weakening confidence in Novartis’s growth profile.
“this is all shaking analyst confidence and the growth profile at Novartis.”
Listen at 0:53
Novartis experienced three clinical trial setbacks within one week.
“The third clinical trial setback in a week.”
Listen at 1:16
Novartis’s news is dragging down Amgen shares.
“shares of Amgen, for instance, which is also in late-stage testing of its own heart disease drug, also being dragged down as a result of this news from Novartis.”
Listen at 1:26
The Boston Scientific cyberattack disrupted order processing, shipping, and manufacturing.
“The cyber attack affected, among other things, information systems that were used to process and ship customer orders. It also impacted manufacturing.”
Listen at 2:13
Cyberattacks remain an ongoing threat to the medtech sector.
“it's an ongoing threat.”
Listen at 2:42
AI will accelerate processes in smart-city systems.
“Essentially, AI will allow in the smart city space to compress a lot of things. The speed will change.”
Listen at 4:25
Dubai responded well to its sudden population increase.
“I think they reacted very well to it.”
Listen at 4:52
Dubai has a long-term urban-planning vision.
“They have a long-term urban planning vision, which again doesn't happen everywhere in the world.”
Listen at 4:54
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Nathan Hager
Boston Scientific
Bloomberg L.P.Listen to the full episode and explore every guest, topic, and moment on PodLume.